Hartmut J. Ehrlich

3.9k total citations
113 papers, 2.9k citations indexed

About

Hartmut J. Ehrlich is a scholar working on Hematology, Immunology and Infectious Diseases. According to data from OpenAlex, Hartmut J. Ehrlich has authored 113 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 29 papers in Immunology and 25 papers in Infectious Diseases. Recurrent topics in Hartmut J. Ehrlich's work include Hemophilia Treatment and Research (23 papers), Influenza Virus Research Studies (21 papers) and Blood Coagulation and Thrombosis Mechanisms (18 papers). Hartmut J. Ehrlich is often cited by papers focused on Hemophilia Treatment and Research (23 papers), Influenza Virus Research Studies (21 papers) and Blood Coagulation and Thrombosis Mechanisms (18 papers). Hartmut J. Ehrlich collaborates with scholars based in Austria, United States and France. Hartmut J. Ehrlich's co-authors include Perry Barrett, Hans Pannekoek, Klaus T. Preissner, Sandor Fritsch, Edward D. Gomperts, Borislava G. Pavlova, Otfried Kistner, Jaap Keijer, Martin Bauer and Raymond Klein Gebbink and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Hartmut J. Ehrlich

112 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hartmut J. Ehrlich Austria	31	878	798	699	653	485	113	2.9k
Gabriele Köhler Germany	38	521 0.6×	1.3k 1.7×	656 0.9×	1.9k 2.9×	1.6k 3.3×	88	5.2k
Peter J. Lachmann United Kingdom	30	595 0.7×	311 0.4×	324 0.5×	1.7k 2.6×	669 1.4×	86	3.1k
Fabienne Tacchini‐Cottier Switzerland	42	405 0.5×	1.3k 1.6×	290 0.4×	2.4k 3.7×	808 1.7×	105	4.7k
Marie‐Cécile Michallet France	21	522 0.6×	341 0.4×	372 0.5×	1.2k 1.8×	1.2k 2.4×	51	2.5k
Tamás Laskay Germany	37	250 0.3×	1.4k 1.7×	391 0.6×	2.5k 3.8×	837 1.7×	81	5.0k
J Y Djeu United States	33	309 0.4×	626 0.8×	484 0.7×	2.1k 3.1×	831 1.7×	63	3.6k
Hanna Jarva Finland	32	279 0.3×	707 0.9×	517 0.7×	1.4k 2.2×	422 0.9×	93	3.0k
Sergio D. Rosenzweig United States	34	353 0.4×	1.0k 1.3×	918 1.3×	2.9k 4.5×	709 1.5×	117	4.2k
Shinjiro Hamano Japan	31	146 0.2×	787 1.0×	632 0.9×	2.3k 3.6×	522 1.1×	125	4.4k
Mark Y. Sangster United States	35	149 0.2×	1.4k 1.7×	765 1.1×	3.6k 5.5×	1.0k 2.1×	68	5.8k

Countries citing papers authored by Hartmut J. Ehrlich

Since Specialization

Citations

This map shows the geographic impact of Hartmut J. Ehrlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hartmut J. Ehrlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hartmut J. Ehrlich more than expected).

Fields of papers citing papers by Hartmut J. Ehrlich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hartmut J. Ehrlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hartmut J. Ehrlich. The network helps show where Hartmut J. Ehrlich may publish in the future.

Co-authorship network of co-authors of Hartmut J. Ehrlich

This figure shows the co-authorship network connecting the top 25 collaborators of Hartmut J. Ehrlich. A scholar is included among the top collaborators of Hartmut J. Ehrlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hartmut J. Ehrlich. Hartmut J. Ehrlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Giavina‐Bianchi, Pedro, Éric Cua, V. Mondain, et al.. (2023). ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial. SHILAP Revista de lepidopterología. 2(4). 100140–100140. 3 indexed citations

Gineste, Paul, Didier Scherrer, Josianne Nitcheu, et al.. (2023). S1097 Correlation of miR-124 Upregulation and PK Parameters in Blood of Patients With Moderate-to-Severe Ulcerative Colitis Receiving Obefazimod for 16 Weeks. The American Journal of Gastroenterology. 118(10S). S836–S836. 1 indexed citations

Scherrer, Didier, et al.. (2022). Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models. Molecular Cancer Therapeutics. 21(12). 1788–1797. 1 indexed citations

Scherrer, Didier, Roman Rouzier, Perry Barrett, et al.. (2016). Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects. Journal of Antimicrobial Chemotherapy. 72(3). dkw458–dkw458. 14 indexed citations

Freissmuth, Michael, Dirk Völkel, Michael Thiele, et al.. (2013). Human Anti-Macrophage Migration Inhibitory Factor Antibodies Inhibit Growth of Human Prostate Cancer Cells In Vitro and In Vivo. Molecular Cancer Therapeutics. 12(7). 1223–1234. 59 indexed citations

Barrett, Perry, Daniel Portsmouth, & Hartmut J. Ehrlich. (2013). Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development. Expert Review of Vaccines. 12(4). 395–413. 17 indexed citations

Dockal, Michael, Rudolf Hartmann, Markus Fries, et al.. (2013). Small Peptides Blocking Inhibition of Factor Xa and Tissue Factor-Factor VIIa by Tissue Factor Pathway Inhibitor (TFPI). Journal of Biological Chemistry. 289(3). 1732–1741. 38 indexed citations

Prymula, Roman, Martin Bauer, Borislava G. Pavlova, et al.. (2012). Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® Junior. Human Vaccines & Immunotherapeutics. 8(6). 736–742. 17 indexed citations

Fritz, Richard, Nicolas Sabarth, Stefan Kiermayr, et al.. (2011). A Vero Cell–Derived Whole-Virus H5N1 Vaccine Effectively Induces Neuraminidase-Inhibiting Antibodies. The Journal of Infectious Diseases. 205(1). 28–34. 50 indexed citations

10.

Holzer, Georg W., Gerald Aichinger, Helga Savidis-Dacho, et al.. (2011). Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine. 29(24). 4132–4141. 30 indexed citations

11.

Tambyah, Paul Anantharajah, Annelies Wilder‐Smith, Borislava G. Pavlova, et al.. (2011). Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine. 30(2). 329–335. 22 indexed citations

12.

O’Nuallain, Brian, Angela D. Williams, Luis Acero, et al.. (2010). Anti-amyloidogenic Activity of IgGs Contained in Normal Plasma. Journal of Clinical Immunology. 30(S1). 37–42. 25 indexed citations

13.

Váradi, Katalin, Hanspeter Rottensteiner, Susanne Vejda, et al.. (2009). Species‐dependent variability of ADAMTS13‐mediated proteolysis of human recombinant von Willebrand factor. Journal of Thrombosis and Haemostasis. 7(7). 1134–1142. 16 indexed citations

14.

Ehrlich, Hartmut J., Markus Müller, Sandor Fritsch, et al.. (2009). A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory Responses. The Journal of Infectious Diseases. 200(7). 1113–1118. 44 indexed citations

15.

Kolarich, Daniel, Martin Pabst, Johannes Stadlmann, et al.. (2008). Glycoproteomic characterization of butyrylcholinesterase from human plasma. PROTEOMICS. 8(2). 254–263. 62 indexed citations

16.

Nemes, László, Toshko Lissitchkov, Anna Klukowska, et al.. (2008). Pharmacokinetics, Efficacy and Safety of IMMUNATE® Solvent/Detergent (IMMUNATE® S/D) in Previously Treated Patients with Severe Hemophilia A: Results of a Prospective, Multicenter, Open-Label Phase III Study. Acta Haematologica. 119(2). 89–97. 3 indexed citations

17.

Reipert, Birgit M., et al.. (2008). Variation of anti‐Fas antibodies in different lots of intravenous immunoglobulin. Vox Sanguinis. 94(4). 334–341. 26 indexed citations

18.

Varga, Gyula, Heinz Leibl, Zoltán Gasztonyi, et al.. (2006). Efficacy and Safety of the New Intravenous Immunoglobulin IGIV 10% in Adults with Chronic Idiopathic Thrombocytopenic Purpura. Transfusion Medicine and Hemotherapy. 33(6). 509–514. 13 indexed citations

19.

Church, Joseph A., Heinz Leibl, Mark R. Stein, et al.. (2006). Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency. Journal of Clinical Immunology. 26(4). 388–395. 64 indexed citations

20.

Handgretinger, R., T. Klingebiel, M Jaquet Herter, et al.. (1994). Comparative analysis of peripheral stem cells collected and transplanted in combination with granulocyte-macrophage and granulocyte colony-stimulating factors.. PubMed. 389. 479–86. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact